𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience

✍ Scribed by Shuqing Lü; Jianmin Wang; Xiaoqian Xu; Xiong Ni; Chongmei Huang; Huiying Qiu; Xiaoxia Hu; Jianmin Yang

Publisher
Carden Jennings Publishing
Year
2008
Tongue
English
Weight
158 KB
Volume
89
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib in combination with dexametha
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience
✍ Weiyan Zheng; Guoqing Wei; Xiujin Ye; Jingsong He; Li Li; Wenjun Wu; Jimin Shi; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 245 KB

## Objective: Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (mm) with an overall response rate of 92% and a cr rate of 18% (alexanian et al, hematology 2007;12(3):235-9), but this regimen has not been tested in the chinese patients. we re

Neurotoxicity of bortezomib therapy in m
Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature
✍ Ashraf Badros; Olga Goloubeva; Jay S. Dalal; Ilyas Can; Jennifer Thompson; Aaron 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 1 views

## Abstract ## BACKGROUND. Bortezomib is active in heavily pretreated multiple myeloma patients; the dose‐limiting toxicity is peripheral neuropathy (PN). ## METHODS. The authors retrospectively reviewed the incidence, severity, and risk factors for PN in 78 patients who received bortezomib. The